Helen Healy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9260661/publications.pdf

Version: 2024-02-01

201575 265120 2,385 42 109 27 h-index citations g-index papers 117 117 117 3398 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Concurrent membranous nephropathy and allergic interstitial nephritis causing acute kidney injury—A case report. Nephrology, 2022, 27, 639-640.	0.7	1
2	SARS-CoV-2 vaccination–associated collapsing glomerulopathy in a kidney transplant recipient. Kidney International, 2022, , .	2.6	5
3	Adenine overload induces ferroptosis in human primary proximal tubular epithelial cells. Cell Death and Disease, 2022, 13, 104.	2.7	13
4	Desmopressin acetate to prevent bleeding in percutaneous kidney biopsy: a systematic review. Internal Medicine Journal, 2021, 51, 571-579.	0.5	6
5	Molecular and functional profiling of apical versus basolateral small extracellular vesicles derived from primary human proximal tubular epithelial cells under inflammatory conditions. Journal of Extracellular Vesicles, 2021, 10, e12064.	5.5	20
6	T-Cell Expression and Release of Kidney Injury Molecule-1 in Response to Glucose Variations Initiates Kidney Injury in Early Diabetes. Diabetes, 2021, 70, 1754-1766.	0.3	7
7	Time-to-event analysis in economic evaluations: a comparison of modelling methods to assess the cost-effectiveness of transplanting a marginal quality kidney. Health Economics Review, 2021, 11, 13.	0.8	3
8	Development and validation of a risk index to predict kidney graft survival: the kidney transplant risk index. BMC Medical Research Methodology, 2021, 21, 127.	1.4	8
9	Bleeding Complications of Percutaneous Kidney Biopsy: Does Gender Matter?. Kidney360, 2021, 2, 1308-1312.	0.9	5
10	Utilization and Costs of Health Care in a Kidney Supportive Care Program. Journal of Palliative Care, 2020, 35, 176-184.	0.4	5
11	The Emerging Role of Renal Tubular Epithelial Cells in the Immunological Pathophysiology of Lupus Nephritis. Frontiers in Immunology, 2020, $11,578952$.	2.2	37
12	Deceased donor kidney allocation: an economic evaluation of contemporary longevity matching practices. BMC Health Services Research, 2020, 20, 931.	0.9	6
13	Development of a Biomarker Panel to Distinguish Risk of Progressive Chronic Kidney Disease. Biomedicines, 2020, 8, 606.	1.4	9
14	Oxidative stress and inflammasome activation in human rhabdomyolysis-induced acute kidney injury. Free Radical Biology and Medicine, 2020, 160, 690-695.	1.3	22
15	Impact of cardiovascular events on mortality and progression of renal dysfunction in a Queensland CKD cohort. Nephrology, 2020, 25, 839-844.	0.7	3
16	Cost-utility analysis in chronic kidney disease patients undergoing kidney transplant; what pays? A systematic review. Cost Effectiveness and Resource Allocation, 2020, 18, 18.	0.6	12
17	The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia. BMC Nephrology, 2020, 21, 58.	0.8	9
18	Role of inflammation and inflammasome activation in human bile cast nephropathy. Nephrology, 2020, 25, 502-506.	0.7	4

#	Article	IF	Citations
19	Donor Kidney Quality and Transplant Outcome: An Economic Evaluation of Contemporary Practice. Value in Health, 2020, 23, 1561-1569.	0.1	10
20	Underlying Histopathology Determines Response to Oxidative Stress in Cultured Human Primary Proximal Tubular Epithelial Cells. International Journal of Molecular Sciences, 2020, 21, 560.	1.8	8
21	Kidney transplant recipient's perceptions of blood testing through microsampling and venepuncture. Bioanalysis, 2020, 12, 873-881.	0.6	12
22	Effector $\hat{I}^3\hat{I}'T$ cells in human renal fibrosis and chronic kidney disease. Nephrology Dialysis Transplantation, 2019, 34, 40-48.	0.4	22
23	Considerable international variation exists in blood pressure control and antihypertensive prescriptionÂpatterns in chronic kidney disease. Kidney International, 2019, 96, 983-994.	2.6	51
24	Specialized Roles of Human Natural Killer Cell Subsets in Kidney Transplant Rejection. Frontiers in Immunology, 2019, 10, 1877.	2.2	21
25	Complex prescribing in chronic kidney disease: role of the renal pharmacist in kidney supportive care in uncovering hydralazineâ€related lupus. Journal of Pharmacy Practice and Research, 2019, 49, 364-367.	0.5	1
26	BMI and its association with death and the initiation of renal replacement therapy (RRT) in a cohort of patients with chronic kidney disease (CKD). BMC Nephrology, 2019, 20, 329.	0.8	15
27	A collaborative, individual-level analysis compared longitudinal outcomes across the International Network of Chronic Kidney Disease (iNETCKD) cohorts. Kidney International, 2019, 96, 1217-1233.	2.6	33
28	Blood pressure management in hypertensive people with non-dialysis chronic kidney disease in Queensland, Australia. BMC Nephrology, 2019, 20, 348.	0.8	9
29	Frequency and Consequences of Acute Kidney Injury in Patients With CKD: A Registry Study in Queensland Australia. Kidney Medicine, 2019, 1, 180-190.	1.0	7
30	Machine learning in predicting graft failure following kidney transplantation: A systematic review of published predictive models. International Journal of Medical Informatics, 2019, 130, 103957.	1.6	63
31	Chronic kidney disease, Queensland: Profile of patients with chronic kidney disease from regional Queensland, Australia: A registry report. Nephrology, 2019, 24, 1257-1264.	0.7	10
32	Human Tissue-Resident Mucosal-Associated Invariant T (MAIT) Cells in Renal Fibrosis and CKD. Journal of the American Society of Nephrology: JASN, 2019, 30, 1322-1335.	3.0	41
33	Biomarkers and the role of mast cells as facilitators of inflammation and fibrosis in chronic kidney disease. Translational Andrology and Urology, 2019, 8, S175-S183.	0.6	21
34	Pigment Nephropathy: Novel Insights into Inflammasome-Mediated Pathogenesis. International Journal of Molecular Sciences, 2019, 20, 1997.	1.8	14
35	Natural Killer Cells in Kidney Health and Disease. Frontiers in Immunology, 2019, 10, 587.	2.2	21
36	Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN). Therapeutic Drug Monitoring, 2019, 41, 703-713.	1.0	7

#	Article	IF	CITATIONS
37	Using machine learning techniques to develop risk prediction models to predict graft failure following kidney transplantation: protocol for a retrospective cohort study. F1000Research, 2019, 8, 1810.	0.8	3
38	Using machine learning techniques to develop risk prediction models to predict graft failure following kidney transplantation: protocol for a retrospective cohort study. F1000Research, 2019, 8, 1810.	0.8	2
39	Tracking patients with advanced kidney disease in the last 12 months of life. Journal of Renal Care, 2018, 44, 115-122.	0.6	7
40	Health service utilisation during the last year of life: a prospective, longitudinal study of the pathways of patients with chronic kidney disease stages 3-5. BMC Palliative Care, 2018, 17, 57.	0.8	5
41	CKD Screening and Surveillance in Australia: Past, Present, and Future. Kidney International Reports, 2018, 3, 36-46.	0.4	15
42	The Kidney Supportive Care programme: characteristics of patients referred to a new model of care. BMJ Supportive and Palliative Care, 2018, , bmjspcare-2018-001630.	0.8	7
43	Body mass index in an Australian population with chronic kidney disease. BMC Nephrology, 2018, 19, 209.	0.8	6
44	The Role of Oxidative Stress and Inflammation in Acute Oxalate Nephropathy Associated With Ethylene Glycol Intoxication. Kidney International Reports, 2018, 3, 1217-1221.	0.4	5
45	Identification and Quantitation of Leukocyte Populations in Human Kidney Tissue by Multi-parameter Flow Cytometry. Bio-protocol, 2018, 8, e2980.	0.2	3
46	Interferon- \hat{I}^3 production by tubulointerstitial human CD56bright natural killer cells contributes to renal fibrosis and chronic kidney disease progression. Kidney International, 2017, 92, 79-88.	2.6	64
47	A Randomized Controlled Trial to Determine the Appropriate Time to Initiate Peritoneal Dialysis after Insertion of Catheter (Timely PD Study). Peritoneal Dialysis International, 2017, 37, 420-428.	1.1	52
48	Ethambutol Is Cleared by a Contemporary High-Flux Hemodialyzer, and Drug Monitoring Ensures Safety and Therapeutic Effect. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	4
49	Unique molecular profile of exosomes derived from primary human proximal tubular epithelial cells under diseased conditions. Journal of Extracellular Vesicles, 2017, 6, 1314073.	5.5	33
50	CKD.QLD: establishment of a chronic kidney disease [CKD] registry in Queensland, Australia. BMC Nephrology, 2017, 18, 189.	0.8	34
51	The increasing rates of acute interstitial nephritis in Australia: a single centre case series. BMC Nephrology, 2017, 18, 329.	0.8	12
52	Spectrum (characteristics) of patients with chronic kidney disease (CKD) with increasing age in a major metropolitan renal service. BMC Nephrology, 2017, 18, 372.	0.8	16
53	A multidisciplinary renal genetics clinic improves patient diagnosis. Medical Journal of Australia, 2016, 204, 58-59.	0.8	31
54	Ethambutol Is a Dialysable Drug, and Drug Monitoring Ensures Safety and Therapeuticity. Open Forum Infectious Diseases, $2016, 3, .$	0.4	0

#	Article	IF	Citations
55	Everolimusâ€induced tubular toxicity in nonâ€renal cancer. Internal Medicine Journal, 2016, 46, 1454-1455.	0.5	4
56	Development and Evaluation of a Scored Sodium Questionnaire–Screening Form for Kidney Disease Patients. , 2016, 26, 159-167.		8
57	A protocol for the identification and validation of novel genetic causes of kidney disease. BMC Nephrology, 2015, 16, 152.	0.8	8
58	Genomics in the renal clinic - translating nephrogenetics for clinical practice. Human Genomics, 2015, 9, 13.	1.4	12
59	The Mechanisms of Human Renal Epithelial Cell Modulation of Autologous Dendritic Cell Phenotype and Function. PLoS ONE, 2015, 10, e0134688.	1.1	12
60	Human proximal tubule epithelial cells modulate autologous B-cell function. Nephrology Dialysis Transplantation, 2015, 30, 1674-1683.	0.4	18
61	Serum 25â€hydroxy vitamin <scp>D</scp> concentrations are more deficient/insufficient in peritoneal dialysis than haemodialysis patients in a sunny climate. Journal of Human Nutrition and Dietetics, 2015, 28, 209-218.	1.3	7
62	Fractalkine–CX3CR1-dependent recruitment and retention of human CD1c+ myeloid dendritic cells by in vitro–activated proximal tubular epithelial cells. Kidney International, 2015, 87, 1153-1163.	2.6	39
63	Laser Capture Microdissection and Multiplex-Tandem PCR Analysis of Proximal Tubular Epithelial Cell Signaling in Human Kidney Disease. PLoS ONE, 2014, 9, e87345.	1.1	12
64	The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia. Orphanet Journal of Rare Diseases, 2014, 9, 98.	1.2	54
65	Development and Validation of a Dietary Screening Tool for High Sodium Consumption in Australian Renal Patients., 2014, 24, 123-134.e3.		21
66	Taming the chronic kidney disease epidemic: a global view of surveillance efforts. Kidney International, 2014, 86, 246-250.	2.6	84
67	ANZSN Renal Supportive Care Guidelines 2013. Nephrology, 2013, 18, 401-454.	0.7	52
68	Increased tubulointerstitial recruitment of human CD141 ^{hi} CLEC9A ⁺ and CD1c ⁺ myeloid dendritic cell subsets in renal fibrosis and chronic kidney disease. American Journal of Physiology - Renal Physiology, 2013, 305, F1391-F1401.	1.3	52
69	A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN): an open-label, randomised controlled trial. BMJ Open, 2013, 3, e003511.	0.8	2
70	Human proximal tubule epithelial cells modulate autologous dendritic cell function. Nephrology Dialysis Transplantation, 2013, 28, 303-312.	0.4	28
71	Splenunculus Masquerading as a Neuroendocrine Tumor of the Pancreatic Allograft in a Kidney-Pancreas Recipient. Transplantation, 2013, 96, e59-e62.	0.5	8
72	Sustained remission of systemic lupus erythematosus related calciphylaxis. Lupus, 2012, 21, 441-444.	0.8	6

#	Article	IF	CITATIONS
73	Pharmacokinetics of Intraperitoneal Gentamicin in Peritoneal Dialysis Patients with Peritonitis (GIPD) Tj ETQq1	1 0.784314 2.2	rgBT /Overlo
74	Factors Associated with Chronic Kidney Disease Progression in Australian Nephrology Practices. Nephron Clinical Practice, 2012, 121, c36-c41.	2.3	5
75	CKD.QLD: chronic kidney disease surveillance and research in Queensland, Australia. Nephrology Dialysis Transplantation, 2012, 27, iii139-iii145.	0.4	26
76	The emerging role of nuclear factor kappa B in renal cell carcinoma. International Journal of Biochemistry and Cell Biology, 2011, 43, 1537-1549.	1.2	67
77	Activated human renal tubular cells inhibit autologous immune responses. Nephrology Dialysis Transplantation, 2011, 26, 1483-1492.	0.4	26
78	Calcific Uremic Arteriolopathy in Peritoneal Dialysis Populations. International Journal of Nephrology, 2011, 2011, 1-9.	0.7	24
79	Ibuprofen-related renal tubular acidosis in pregnancy. Obstetric Medicine, 2011, 4, 122-124.	0.5	6
80	Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 412-425.	2.2	20
81	Randomised Controlled Trial to determine the appropriate time to initiate peritoneal dialysis after insertion of catheter to minimise complications (Timely PD study). BMC Nephrology, 2010, 11, 11.	0.8	23
82	Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. Nephrology Dialysis Transplantation, 2010, 25, 920-926.	0.4	13
83	Inhibition of nuclear factor kappa B attenuates tumour progression in an animal model of renal cell carcinoma. Nephrology Dialysis Transplantation, 2010, 25, 1462-1474.	0.4	13
84	Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor. Angiogenesis, 2009, 12, 365-379.	3.7	21
85	Assessment of arterial stiffness, oxidative stress and inflammation in acute kidney injury. BMC Nephrology, 2009, 10, 15.	0.8	6
86	Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study. BMC Nephrology, 2009, 10, 42.	0.8	9
87	Comparison of markers of oxidative stress, inflammation and arterial stiffness between incident hemodialysis and peritoneal dialysis patients $\hat{a}\in$ an observational study. BMC Nephrology, 2009, 10, 8.	0.8	15
88	Point of care measurement of plasma creatinine in critically ill patients with acute kidney injury. Anaesthesia, 2009, 64, 403-407.	1.8	38
89	Astaxanthin vs placebo on arterial stiffness, oxidative stress and inflammation in renal transplant patients (Xanthin): a randomised controlled trial. BMC Nephrology, 2008, 9, 17.	0.8	31
90	Birth Weight and Stages of CKD: A Case-Control Study in an Australian Population. American Journal of Kidney Diseases, 2008, 52, 1070-1078.	2.1	34

#	Article	IF	CITATIONS
91	Phosphorylation of caveolin-1 is anti-apoptotic and promotes cell attachment during oxidative stress of kidney cells. Pathology, 2008, 40, 694-701.	0.3	17
92	Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure. Clinical and Experimental Nephrology, 2006, 10, 201-209.	0.7	4
93	Pyrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines. Nephrology Dialysis Transplantation, 2006, 21, 3377-3388.	0.4	49
94	High ambient glucose is effect neutral on cell death and proliferation in human proximal tubular epithelial cells. American Journal of Physiology - Renal Physiology, 2005, 289, F401-F409.	1.3	25
95	Superiority of Icodextrin Compared with 4.25% Dextrose for Peritoneal Ultrafiltration. Journal of the American Society of Nephrology: JASN, 2005, 16, 546-554.	3.0	132
96	High molecular weight plasma proteins induce apoptosis and Fas/FasL expression in human proximal tubular cells. Nephrology Dialysis Transplantation, 2005, 20, 50-58.	0.4	31
97	Effects of Early and Late Intervention with Epoetin on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4): Results of a Randomized Clinical Trial. Journal of the American Society of Nephrology: JASN, 2004, 15, 148-156.	3.0	206
98	Development, Prevention, and Potential Reversal of Left Ventricular Hypertrophy in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2004, 15, 1640-1647.	3.0	75
99	Treatments conferring renoprotection in patients with Nephrotic Syndrome. Nephrology, 2002, 7, S16-S20.	0.7	0
100	Treatments conferring renoprotection in patients with Nephrotic Syndrome. Nephrology, 2002, 7, S16-S20.	0.7	2
101	Evaluation of a Novel Vitamin E Coated Cellulosic Membrane Hollow Fiber Dialyzer. ASAIO Journal, 2001, 47, 66-73.	0.9	14
102	Chronic inflammatory demyelinating polyradiculoneuropathy and severe peripheral oedema: a renal explanation. Journal of Clinical Neuroscience, 2000, 7, 148-149.	0.8	8
103	Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrology Dialysis Transplantation, 1999, 14, 2698-2703.	0.4	85
104	Hyperhomocysteinaemia in end-stage renal failure patients: Effect of low-dose supplementation with folic acid. Nephrology, 1998, 4, 413-418.	0.7	1
105	The clinical pharmacologic profile of reboxetine: does it involve the putative neurobiological substrates of wellbeing?. Journal of Affective Disorders, 1998, 51, 313-322.	2.0	20
106	Oxidation of low density lipoprotein in hemodialysis patients: effect of dialysis and comparison with matched controls. Atherosclerosis, 1997, 129, 199-205.	0.4	34
107	Lowâ€density lipoprotein subfraction profiles in dialysis patients. Nephrology, 1997, 3, 169-177.	0.7	7
108	RENAL COMPLICATIONS OF CYTOTOXIC THERAPY. Australian and New Zealand Journal of Medicine, 1983, 13, 531-539.	0.5	8

#	Article	IF	CITATIONS
109	Cost-Effectiveness and Budget Impact Analysis of Implementing a 'Soft Opt-Out' System for Kidney Donation in Australia. Applied Health Economics and Health Policy, 0, , .	1.0	0